مقالات پذیرفته شده در هشتمین کنگره بین المللی زیست پزشکی
Biomarkers Discovery in Acute Myeloid Leukemia Based on Multi-omics Approaches
Biomarkers Discovery in Acute Myeloid Leukemia Based on Multi-omics Approaches
Fatemeh Sadat Shafiei,1,*Mohammad Rafiee,2Saeid Abroun,3Sadaf Vahdat,4
1. Department of Medical Laboratory Sciences, School of Paramedical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran 2. Department of Medical Laboratory Sciences, School of Paramedical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran 3. Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran 4. Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Introduction: Acute myeloid leukemia (AML) is the most common acute leukemia in adults and has the highest fatality rate. Patients aged 65 and above exhibit the poorest prognosis, with a mere 30% survival rate within one year. The current method for AML diagnosis involves assessing the morphological characteristics of myeloid cells, characterizing specific cell surface and intracellular markers through immunophenotyping, conducting conventional cytogenetic tests, and screening for genetic abnormalities in bone marrow and peripheral blood samples. Ongoing technological advancements aim to pinpoint more precise AML biomarkers, crucial for monitoring minimal residual disease during follow-up periods. This unmet necessity, coupled with AML's inherent tumor attributes, contributes to its elevated mortality rate among all leukemias, with an overall 5-year survival rate of less than 50%. Consequently, there is a pressing need for enhanced AML biomarkers to enhance diagnosis, treatment, and prognosis forecasting.
Methods: The past decade has witnessed significant progress in sequencing and biotechnological approaches, facilitating the widespread adoption of various omics technologies such as genomic/transcriptomic sequencing and proteomic/metabolomic mass spectrometry for analyzing samples from AML patients. By integrating data from multiple omics sources, our understanding of the disease has expanded, leading to the identification of valuable AML biomarkers. In this review, we discuss the application of multi-omics technologies in AML research for the discovery of novel biomarkers and the enhancement of clinical evaluations.
Results: By integrating data from multiple omics sources, our understanding of the disease has expanded, leading to the identification of valuable AML biomarkers. In this review, we discuss the application of multi-omics technologies in AML research for the discovery of novel biomarkers and the enhancement of clinical evaluations.
Conclusion: Multi-omics approaches that integrate the data from distinct levels of the cellular organization, i.e., from genes to metabolites, have been reported, which offer new perspectives for innovative AML diagnostics and therapeutics.